Forte Biosciences (FBRX) Operating Leases (2019 - 2020)
Forte Biosciences (FBRX) posted quarterly Operating Leases of $3.9 million for Q1 2020, down 59.07% year-over-year from $9.6 million in Q2 2019, and down 2.86% quarter-over-quarter from $4.0 million in Q4 2019.
Forte Biosciences (FBRX) Operating Leases (2019 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Operating Leases for 2 consecutive years, with $3.9 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Operating Leases fell 59.07% year-over-year to $3.9 million; the TTM figure through Mar 2020 stood at $3.9 million (down 59.07% YoY), while the FY2019 annual figure was $4.0 million, changed N/A from the prior year.
- Operating Leases declined to $3.9 million in Q1 2020 per FBRX's latest filing, from $4.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $9.6 million in Q1 2019 and bottomed at $3.9 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 3.91 Mn |
| Dec 31, 2019 | 4.03 Mn |
| Sep 30, 2019 | 9.12 Mn |
| Jun 30, 2019 | 9.36 Mn |
| Mar 31, 2019 | 9.56 Mn |